文献速递骨软组织肉瘤与黑色素瘤

阿帕替尼联合卡瑞利珠单抗一线治疗晚期肢端黑色素瘤:开放标签单臂2期试验

Apatinib combined with camrelizumab in advanced acral melanoma patients: An open-label, single-arm phase 2 trial.
PubMed 文献 · Eur J Cancer · 2023-01-12

该开放标签单臂2期试验纳入30例晚期初治肢端黑色素瘤患者,给予阿帕替尼250 mg每日一次联合卡瑞利珠单抗200 mg每两周一次静脉给药,每28天为一周期。客观缓解率为24.1%,疾病控制率为82.8%,中位无进展生存期7.39个月,中位总生存期13.4个月。3-4级治疗相关毒性包括转氨酶升高、蛋白尿、白细胞减少、呕吐、腹泻和药物性肝损伤,无治疗相关死亡。

要点

  • 客观缓解率24.1%,其中部分缓解5例、完全缓解2例,疾病控制率82.8%。
  • 中位无进展生存期7.39个月(CI 3.65-9.92),中位总生存期13.4个月(CI 1.9-25.0)。
  • 3-4级治疗相关毒性包括转氨酶升高、蛋白尿、白细胞减少、呕吐、腹泻和药物性肝损伤,无治疗相关死亡。

核心结论

  • 阿帕替尼联合卡瑞利珠单抗一线治疗晚期肢端黑色素瘤显示可控的安全性及合理的抗肿瘤活性。

研究设计与样本

  • 开放标签、单臂2期试验(NCT03955354),纳入病理确诊的局部不可切除或转移性初治肢端黑色素瘤患者。
  • 患者接受阿帕替尼250 mg每日一次口服联合卡瑞利珠单抗200 mg每两周一次静脉给药,每28天为一周期。
  • 主要终点为客观缓解率,次要终点为疾病控制率、总生存期、无进展生存期和安全性。
  • 2015年1月至2022年1月期间共入组30例患者。

主要发现

  • 入组30例患者中21例(70.0%)为IV期,中位肿瘤负荷为50 mm(范围11-187)。
  • 客观缓解率为24.1%,29例可评估患者中7例有抗肿瘤反应,包括部分缓解5例和完全缓解2例。
  • 疾病控制率为82.8%,中位无进展生存期7.39个月(CI 3.65-9.92),中位总生存期13.4个月(CI 1.9-25.0)。
  • 3-4级治疗相关毒性包括转氨酶升高、蛋白尿、白细胞减少、呕吐、腹泻和药物性肝损伤,其中3级50.5%、4级3.3%,无治疗相关死亡。
  • TTN、MUC16、VPS13D、ALPK2和SCUBE1突变与生存结局显示显著改变。

临床怎么用

  • 作者结论认为阿帕替尼联合卡瑞利珠单抗一线治疗晚期肢端黑色素瘤显示可控的安全性及合理的抗肿瘤活性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: At present, immune monotherapy and combination therapy has not shown satisfactory effects on acral melanoma, and still no standard treatment is available for advanced acral melanoma. Here, a phase II trial was performed to explore the safety and efficacy of apatinib combined with camrelizumab in advanced acral melanoma patients as first-line therapy (NCT03955354). METHODS: Patients with pathologically confirmed, locally unresectable or metastatic treatment native acral melanoma received 250 mg apatinib once daily and camrelizumab 200 mg once every two weeks intravenously every 28-day cycle. The primary end-point was objective response rate and the secondary end-points were disease control rate, overall survival, progression-free survival and safety. RESULTS: Thirty patients were recruited between January 2015 and January 2022. Among them, 21 (70.0%) had stage IV, and a median tumour burden was 50 mm (range: 11-187). Objective response rate was 24.1%, and 7 of 29 patients had an anti-tumour response, including partial response (n = 5) and complete response (n = 2). Disease control rate was 82.8%, median progression-free survival was 7.39 months (confidence interval: 3.65-9.92), and median overall survival was 13.4 months (confidence interval: 1.9-25.0). Grade 3-4 treatment-related toxicity (grade 3 50.5%; grade 4 3.3%) included transaminase elevations, proteinuria, leukocytopenia, vomiting, diarrhea and drug-induced liver injury. No treatment-related mortality occurred. The mutations of TTN, MUC16, VPS13D, ALPK2 and SCUBE1 showed significant alterations with survival outcome. CONCLUSIONS: Apatinib combined with camrelizumab showed manageable safety profile and reasonable anti-tumour activity in advanced acral melanoma patients as first-line therapy.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Wang X, Wu X, Yang Y, et al. Apatinib combined with camrelizumab in advanced acral melanoma patients: An open-label, single-arm phase 2 trial. Eur J Cancer. 2023. PMID: 36753834. doi:10.1016/j.ejca.2022.12.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。